Quinine Sulfate for Muscle Cramps in Amyotrophic Lateral Sclerosis: A Randomized, Double‐Blind Crossover Trial
Muscle & Nerve · 2025
DOI: 10.1002/mus.28440 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Muscle & Nerve, 2025. Verfasst von Charlotte Vogt und 3 weiteren Autor:innen. Beteiligte Einrichtung: Neuromuscular Diseases Unit/ALS Clinic, Kantonsspital St Gallen, St Gallen, Gallen, Switzerland. Hauptthemen laut MEDLINE: Quinine, Muscle Cramp, Amyotrophic Lateral Sclerosis. Die Arbeit nennt 22 Literaturangaben. Gefördert von: Swiss ALS foundation, Hänseler AG.
Abstract (Originalsprache)
Introduction/Aims Many patients with amyotrophic lateral sclerosis (ALS) experience muscle cramps during the course of the disease. This study aimed to evaluate the efficacy of orally administered quinine sulfate for muscle cramps in ALS patients.
Methods
We conducted a randomized, double‐blind, placebo‐controlled crossover trial in ALS patients experiencing daily muscle cramps. After a two‐week run‐in period, patients were assigned to receive 250 mg quinine sulfate once daily, followed by a placebo or vice versa. Each treatment period lasted 2 weeks and was followed by a 4‐week washout period. Patients used a daily diary to rate muscle cramp intensity on the numeric rating scale (NRS) and record muscle cramp frequency. The primary outcome measure was change in cramp intensity; coprimary outcome measures were number of muscle cramps during daytime and nighttime.
Results
Data from four women and three men were included in the analysis, all of whom reported a notable reduction in cramp intensity and frequency, leading them to continue the medication. Quinine sulfate was well‐tolerated, with two patients reporting mild tinnitus. Cramp intensity was significantly reduced by 48% ( p = 0.042). Further, the number of daytime muscle cramps declined significantly ( p = 0.024).
Discussion
Our findings suggest the potential efficacy of quinine sulfate in reducing muscle cramp intensity and frequency in ALS patients. However, the small sample size ( n = 7) limits generalizability. Larger, multicenter studies are needed to confirm these results and fully assess its safety, serious adverse events, and therapeutic potential.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Neuromuscular Diseases Unit/ALS Clinic, Kantonsspital St Gallen, St Gallen, Gallen, Switzerland.
ORCID-Profile: Charlotte Vogt
Förderung
- Swiss ALS foundation
- Hänseler AG
Zitieren
APA
Vogt, C., Weber, M., Schneider, U., & Neuwirth, C. (2025). Quinine Sulfate for Muscle Cramps in Amyotrophic Lateral Sclerosis: A Randomized, Double‐Blind Crossover Trial. Muscle & Nerve. https://doi.org/10.1002/mus.28440
Vancouver
Vogt C, Weber M, Schneider U, Neuwirth C. Quinine Sulfate for Muscle Cramps in Amyotrophic Lateral Sclerosis: A Randomized, Double‐Blind Crossover Trial. Muscle & Nerve. 2025. doi:10.1002/mus.28440
BibTeX
@article{Vogt2025,
author = {Vogt, Charlotte and Weber, Markus and Schneider, Ursula and Neuwirth, Christoph},
title = {Quinine Sulfate for Muscle Cramps in Amyotrophic Lateral Sclerosis: A Randomized, Double‐Blind Crossover Trial},
journal = {Muscle & Nerve},
year = {2025},
doi = {10.1002/mus.28440}
}
EUVIMED